Documentación Científica Cardiorenal

Algoritmos: Protocolos de anticoagulación en pacientes con cáncer activo

Epidemiología del ictus cardioembólico y su asociación con la penetración de los ACOD en España

Head-to-head efficacy and safety of rivaroxaban, apixaban, and dabigatran in an observational nationwide targeted trial

Incidence of cardiovascular events in patients with atrial fibrillation anticoagulated with rivaroxaban after 2.5 years of follow-up: not all is stroke or bleeding

Introducción a la Unidad de Cardio-Onco-Hematología

Mejorar la prevención de la trombosis y las complicaciones cardiovasculares durante la pandemia de COVID-19

Outcomes and factors associated with mortality in patients with atrial fibrillation and heart failure: FARAONIC study

Outcomes and predictive value of the 2MACE score in patients with atrial fibrillation treated with rivaroxaban in a prospective, multicenter observational study: The EMIR study

Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain

Rivaroxaban for the prevention of outcomes in patients with atrial fibrillation in clinical practice: an indirect comparison of national and international registries

Rivaroxaban vs Vitamin K Antagonist in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease

Thromboembolic and bleeding events with rivaroxaban in clinical practice in Spain: impact of inappropriate doses (the EMIR study)

Use of rivaroxaban attenuates renal function impairment in patients with atrial fibrillation: insights of the EMIR study

Vascular protection with rivaroxaban in the comprehensive management of atrial fibrillation

Material Educacional DM2

Practical Patient Care Considerations With Use of Vericiguat After Worsening Heart Failure Events

Abordaje terapéutico del paciente con ICFEr. Papel del vericiguat

El impacto emocional de la IC

Infografía sobre la descompensación de la IC

Integrando y personalizando el tratamiento en ICFEr